ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,291.34
0.15%
Dow Jones
38,711.29
0.36%
US Dollar vs MXN
17.8201
0.02%
Brent Oil
77.455
0.45%
Bitcoin
70,958.56
0.56%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. uniQure NV (QURE)

  7. uniQure NV (QURE) Noticias

QURE

uniQure NV (QURE)

uniQure NV
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:QURE
FechaHoraFuenteTítuloSímboloCompañía
03/06/202406:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
03/06/202406:05GlobeNewswire Inc.uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
07/05/202406:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
07/05/202406:05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
05/03/202416:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
28/02/202407:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
28/02/202406:05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/02/202415:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
13/02/202415:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202306:05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
11/12/202318:30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202306:05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202306:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
07/11/202306:05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/10/202309:00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
26/10/202313:38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
26/10/202313:14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202306:05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
06/10/202305:33Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:QUREuniQure NV
06/10/202305:32Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:QUREuniQure NV
05/10/202306:05GlobeNewswire Inc.uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage ProgramsNASDAQ:QUREuniQure NV
02/10/202320:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QUREuniQure NV
05/09/202312:59Dow Jones NewsRe/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600NASDAQ:QUREuniQure NV
05/09/202306:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
01/09/202317:51PR Newswire (US)Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600NASDAQ:QUREuniQure NV
01/08/202306:05GlobeNewswire Inc.uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
26/06/202306:11GlobeNewswire Inc.uniQure Announces Leadership Addition to Support Advancement of Clinical ProgramsNASDAQ:QUREuniQure NV
22/06/202316:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QUREuniQure NV
21/06/202306:05GlobeNewswire Inc.uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
20/06/202316:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QUREuniQure NV
 Showing the most relevant articles for your search:NASDAQ:QURE

Su Consulta Reciente

USOTC
FAHE
Fahey Banking (CE)
BIT
P1XUE3
NLBNPIT1XUE3 20240621 14
BIT
P1XWT7
NLBNPIT1XWT7 20351221 16...
BIT
P1WR05
NLBNPIT1WR05 20240620 5000
KUCN
MAHABTC
MahaDAO
NASDAQ
AAYZGXX
Royal Bank of Canada Poi...
NASDAQ
RFDI
First Trust RiverFront D...
AMEX
AUGR
BIT
P1UYG6
NLBNPIT1UYG6 20991231 28...
BIT
P1XZA0
NLBNPIT1XZA0 20991231 11...
BOV
CTKA4R
KARSTEN PN
USOTC
AIXXF
AIXTRON SE Namen AKT (PK)
USOTC
RPGLD
Endurance RP (PK)
NASDAQI
XAUSEK1630GMTSEK
Gold Sweden Krona 1630GM...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados